Agenus Inc. (NASDAQ: AGEN) is a Healthcare company (Biotechnology) with a market capitalization of $281M. The Maz Rating grades it against the other companies in its sector.
Agenus Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.21, Agenus Inc. trades at 8.3x trailing earnings and 2.1x sales, with an EV/EBITDA of 2.8. Over the last twelve months it generated about $137M of revenue and $34M of net income. It runs an operating margin of 38.9% and a net margin of 23.0%. It shows return on equity of -15.5%, return on invested capital of 108.3% and a free cash flow yield of -36.9%. On the balance sheet: a debt-to-equity ratio of -0.37 and a current ratio of 0.73. Over the past 52 weeks the share price ranged from $2.71 to $10.31, with a beta of 1.52.
Agenus Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.